CMG PHARMACEUTICAL CO LTD |
End-of-day quote
Other stock markets
|
||
| - | - |
|
| Sales 2022 | 82.2B 59.59M 0 | Sales 2023 | 93.91B 68.08M 0 | Capitalization | 335B 243M 0 |
|---|---|---|---|---|---|
| Net income 2022 | -388M -281K - | Net income 2023 | 6.46B 4.68M - | EV / Sales 2022 | 2.77 x |
| Net cash position 2022 | 71.1B 51.55M 0 | Net cash position 2023 | 42.71B 30.96M 0 | EV / Sales 2023 | 3.11 x |
| P/E ratio 2022 |
-717
x | P/E ratio 2023 |
52.4
x | Employees | - |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 74.16% |
More Fundamentals
* Assessed data
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Ju-Hyung Lee
CEO | Chief Executive Officer | 62 | 15-11-05 |
Sang-Ki Kim
BRD | Director/Board Member | 62 | 15-04-26 |
In-Chul Jung
IRC | Investor Relations Contact | 53 | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ju-Hyung Lee
CEO | Chief Executive Officer | 62 | 15-11-05 |
Sang-Ki Kim
BRD | Director/Board Member | 62 | 15-04-26 |
Seung-Chul Han
BRD | Director/Board Member | 60 | - |
CMG Pharmaceutical Co., Ltd is a Korea-based company specialized in the manufacture of pharmaceuticals. The Companyâs products include antibiotics, antifungals, antivirus, anti-tuberculousis drugs, peptic ulcer drugs, dementia remedies, antihistamines and antipyretics, among others. It is also engaged in the manufacture of stone products. The Company mainly distributes is pharmaceutical products within domestic markets, as well as to overseas markets. On April 16, 2013, the Company changed its name from SKYNEWPHARM. Co., Ltd to CMG Pharmaceutical Co., Ltd.
Sector
Pharmaceuticals
Calendar
2024-05-09
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +18.59% | 22.25B | |
| +13.82% | 14.39B | |
| +12.83% | 13.55B | |
| +38.02% | 11.27B | |
| -9.80% | 6.95B | |
| -0.05% | 6.79B | |
| -8.87% | 5.73B | |
| +6.29% | 5.01B | |
| -8.24% | 4.51B |
